$31.09
-2.98(-8.76%)
Mkt Cap $1.5B
$3.02
$40.13
52-Week Range
At a Glance
AI-generatedNanobiotix continues to operate with negative cash flows, consistent with its development stage, as the company advances its oncology pipeline while managing expenses in line with strategic priorities following recent licensing changes.
6-K
Nanobiotix reported full year 2025 financial results, extended its cash runway into early 2028, and provided updates on clinical progress for JNJ-1900 (NBTXR3) and its Curadigm Nanoprimer platform.$1.5B
Market Cap
$5M
Revenue
-$45M
Net Income
Employees108
Fundamentals
How The Business Makes Money
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001760854
ISINUS63009J1079
CUSIP63009J107
Phone33 1 40 26 04 70
Address60 rue de Wattignies, Paris, 75012, FR
SEC EDGAR